Hemogenyx Pharmaceuticals (LON:HEMO) Hits New 1-Year Low – Here’s What Happened

Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO) hit a new 52-week low on Monday . The stock traded as low as GBX 1.05 ($0.01) and last traded at GBX 1.16 ($0.02), with a volume of 64623211 shares. The stock had previously closed at GBX 1.27 ($0.02).

Hemogenyx Pharmaceuticals Stock Performance

The stock has a market capitalization of £15.54 million, a P/E ratio of -116.00 and a beta of 3.14. The company has a fifty day moving average of GBX 1.39 and a two-hundred day moving average of GBX 1.39. The company has a debt-to-equity ratio of 92.09, a current ratio of 4.38 and a quick ratio of 6.72.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.